Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor.
Dragun
D
D
Department of Nephrology Medical Faculty of the Charité Campi Mitte, Berlin, Germany. duska.dragun@charite.de
Bräsen
J H
JH
Schönemann
C
C
Fritsche
L
L
Budde
K
K
Neumayer
H-H
HH
Luft
F C
FC
Wallukat
G
G
D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers; D000917:Antibody Formation; D001706:Biopsy; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D019808:Losartan / Q000627:therapeutic use; D008285:Major Histocompatibility Complex; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D044140:Receptor, Angiotensin, Type 1 / Q000276:immunology*
D000305:Adrenal Cortex Hormones; D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D011725:Pyridines; D044140:Receptor, Angiotensin, Type 1; C073402:PD 123319; D016572:Cyclosporine; D009173:Mycophenolic Acid; D019808:Losartan